In the occasion of its 20th anniversary, the European Medicines Agency (EMA) has launched a book detailing his career and achievements in different courses of action in relation to the approvation process and evaluation of drugs. Among the issues that the publication highlights is included a section on meeting the needs of rare disease patients and their recent success in bringing transparency to the clinical trial process .
In 2001, was created at the EMA's Committee for Orphan Medicinal Products (COMP), whose members include three people representing patients' associations. This is a milestone in the management procedures of the EMA, and ensures that the views, experiences and suggestions of patients are considerated in the process of designation and evaluation of orphan drugs.
The publication is available in electronic format for download by the following link.